Efficacy of adjuvant intrastromal and combination of intrastromal and intracameral voriconazole in Aspergillus fumigatus-induced moderate fungal keratitis in rabbits
BACKGROUND There is no in vivo evidence for the effectiveness of adjuvant intrastromal and combination of intrastromal and intracameral voriconazole (VCZ) for treating Aspergillus fumigatus keratitis. This study aimed to compare the efficacy of both agents against it.
METHODS A randomized, masked, controlled experimental study was conducted on 11 albino New Zealand white rabbits in which moderate fungal keratitis was induced by inoculating spores of A. fumigatus to the cornea. The rabbits were allocated into 3 groups: 50 μg/0.1 ml intrastromal VCZ injection, 50 μg/0.1 ml intrastromal VCZ and intracameral VCZ injections, and topical VCZ (control). The treatment was given 5 days after inoculation. Epithelial defect, infiltrate size, corneal ulcer depth, and hypopyon were evaluated clinically. Histopathological and mycological examinations were also done 14 days after treatment.
RESULTS All rabbits in the adjuvant treatment groups demonstrated a tendency of a better clinical response with decreasing size of epithelial defect (p = 0.679) and infiltrate (p = 0.755) than in the control group. Direct microscopy, corneal culture, and chop corneal tissue culture were still positive in most of the rabbits from all groups. Histopathological examination showed an increase of inflammatory cells after treatment in all groups, especially in rabbits which were inoculated with A. fumigatus spores in both eyes.
CONCLUSIONS An adjuvant combination of intrastromal and intracameral VCZ showed a tendency of better clinical response for A. fumigatus-induced moderate fungal keratitis in rabbits.
Keay LJ, Gower EW, Iovieno A, Oechsler RA, Alfonso EC, Matoba A, et al. Clinical and microbiological characteristics of fungal keratitis in the United States, 2001-2007: a multicenter study. Ophthalmology. 2011;118(5):920-6. https://doi.org/10.1016/j.ophtha.2010.09.011
Montgomery ML, Fuller KK. Experimental models for fungal keratitis: an overview of principles and protocols. Cells. 2020;9(7):1713. https://doi.org/10.3390/cells9071713
Niu L, Liu X, Ma Z, Yin Y, Sun L, Yang L, et al. Fungal keratitis: pathogenesis, diagnosis and prevention. Microb Pathog. 2020;138:103802. https://doi.org/10.1016/j.micpath.2019.103802
Keay J, Gower EW, Lovieno A, Oechsler RA, Alfonso EC, Matoba A, et al. Clinical and microbiological characteristics of fungal keratitis in the United States, 2001-2007: a multicenter study. Ophthalmology. 2011;118(5):920-6. https://doi.org/10.1016/j.ophtha.2010.09.011
Darsini IP, Edwar L. Descriptive study: demographic profile, clinical characteristic, and management of corneal ulcer in Infection Immunology division Cipto Mangunkusumo Kirana hospital from January to December 2013 (Unpublished). Jakarta: Universitas Indonesia; 2015. Indonesian.
American Academy of Ophthalmology. Infectious diseases/external eye: microbial and parasitic infections. In: American Academy of Ophthalmology, editors. External disease and cornea. San Francisco: American Academy of Ophthalmology; 2014-2015. p. 154-6.
Kalkanci A, Ozdek S. Ocular fungal infections. Curr Eye Res. 2011;36(3):179-89. https://doi.org/10.3109/02713683.2010.533810
Sharma B, Kataria P, Anand R, Gupta R, Kumar K, Kumar S, et al. Efficacy profile of intracameral amphotericin B. The often forgotten step. Asia Pac J Ophthalmol. 2015;4(6):360-6. https://doi.org/10.1097/APO.0000000000000107
Park CH, Lee HS, Chung SK. Toxicity of intrastromal voriconazole injection on corneal endothelium in rabbits. Cornea. 2014;33(9):928-34. https://doi.org/10.1097/ICO.0000000000000181
Lekhanont K, Nonpassopon M, Nimvorapun N, Santanirand P. Treatment with intrastromal and intracameral voriconazole in 2 eyes with Lasiodiplodia theobromae keratitis: case reports. Medicine. 2015;94(6):e541. https://doi.org/10.1097/MD.0000000000000541
Haddad RS, El-Mollayess GM. Combination of intracameral and intrastromal voriconazole in the treatment of recalcitrant Acremonium fungal keratitis. Middle East Afr J Ophthalmol. 2012;19(2):265-8. https://doi.org/10.4103/0974-9233.95271
Monika, Chugh JP, Chauhan RS, Rathi A. Role of intrastromal voriconazole in recalcitrant fungal keratitis. Int J Med Ophthalmol. 2019;1(2):37-9. https://doi.org/10.33545/26638266.2019.v1.i2a.19
Pfister RR, Paterson CA, Hayes SA. Topical ascorbate decreases the incidence of corneal ulceration after experimental alkali burns. Invest Ophthalmol Vis Sci. 1978;17(10):1019-24.
Lee SY, Ryu EH, Moon SK, Kim HJ, Woo SY, Cho MS, et al. The efficacy of intravitreal gatifloxacin in experimental S. epidermidis endophthalmitis. J Korean Ophthalmol Soc. 2008;49(4):651-60. https://doi.org/10.3341/jkos.2008.49.4.651
Blanco JL, Garcia ME. Immune response to fungal infections. Vet Immunol Immunopathol. 2008;125(1-2):47-70. https://doi.org/10.1016/j.vetimm.2008.04.020
Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamics profile of voriconazole. Clin Pharmacokinet. 2006;45(7):649-63. https://doi.org/10.2165/00003088-200645070-00002
Namrata S, Vajpayee RB, Hugh RT, Peter RL. Fungal keratitis In: Corneal ulcers: diagnosis and management. 1st ed. New Delhi: Jaypee Brothers and Medical Publishers; 2008.
Thomas PA. Aspergillus keratitis. In: Pasqualotto AC, editor. Aspergillosis: from diagnosis to prevention. India: Springer Science + Business Media; 2010. p. 973-96. https://doi.org/10.1007/978-90-481-2408-4_57
Thomas PA, Kaliamurthy J. Mycotic keratitis: epidemiology, diagnosis and management. Clin Microbiol Infect. 2013;19(3):210-20. https://doi.org/10.1111/1469-0691.12126
Bourget A, Guyonnet A, Donzel E, Guilllot J, Pignon C, Chahory S. Keratomycosis in a pet rabbit (Oryctolagus cuniculus) treated with topical 1% terbinafine ointment. Vet Ophthalmol. 2016;19(6):504-9. https://doi.org/10.1111/vop.12318
Shoham S, Levitz SM. The immune response to fungal infections. Br J Haematol. 2005;129(5):569-82. https://doi.org/10.1111/j.1365-2141.2005.05397.x
Copyright (c) 2021 Dyah Tjintya Sarika, Melva Louisa, Anna Rozaliyani, Evelina -, Made Susiyanti
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.